In the fourth quarter of 2024, BB Biotech shares posted a total return of -2.7% in CHF and -3.5% in EUR. NAV performance improved, rising by 2.7% in CHF and 2.8% in EUR, though it declined by 4.3% in ...

Veradigm said today it was extending the plan, set to expire on Feb. 26, 2025, through to Aug. 20. Also, to reflect drops in the price of company common stock, the plan updates the exercise price for ...

Baron Partners Fund increased in the fourth quarter of 2024, outperforming its benchmark, the Russell Midcap Growth Index.

Baron FinTech Fund increased in the fourth quarter of 2024, outperforming its benchmark, the FactSet Global FinTech Index.

Chris Cimaglio of PivotPoint Business Solutions talks about exploring ESOPs as a path to legacy and growth in horticulture.